PharmaLytica 2021 Hyderabad review.

Aurobindo Pharma Q3 results reports an over four-fold jump in its consolidated net profit to ₹2,946.32 crore

The consolidated revenue from operations of the company stood at Rs 6,364.91 crore. It was Rs 5,895 crore for the same period a year ago

10 February, 2021 Mumbai; Aurobindo Pharma reported an over four-fold jump in its consolidated net profit to ₹2,946.32 crore for the quarter ended December 31, 2020 mainly on account of one time exceptional gains.

Aurobindo Pharma, Managing Director N Govindarajan said, we maintained growth momentum in our revenue and profitability despite COVID challenges. We are witnessing steady progress in our specialty pipeline and continue to focus on growing our business, improving efficiencies and productivity.

The company had posted a net profit of ₹705.31 crore for the corresponding period of the previous fiscal, Aurobindo said in a BSE filing.

The consolidated revenue from operations of the company stood at Rs 6,364.91 crore. It was Rs 5,895 crore for the same period a year ago, it added.

The profit before tax includes exceptional items of Rs 2,813.89 crore for the quarter ended in December consists of disposal of business assets of a wholly-owned step-down subsidiary, Natrol LLC, on account of remeasurement of equity interest in Eugia Pharma Specialties Ltd and impairment charges taken considering the difficult economic conditions and the continued impact of COVID 19 in certain markets towards product-related intangibles and goodwill, the filing said.

The board has approved a third interim dividend of ₹1.5 per equity share of Re 1/- for the financial year 2020-21, the filing said. Shares of Aurobindo Pharma closed at ₹967.85 per scrip on BSE, up 0.88% from its previous close.

×

This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More